Journal of the National Comprehensive Cancer Network 2024

4 papers
The 2024 edition of the Journal of the National Comprehensive Cancer Network features research addressing clinical management, healthcare delivery, and emerging technologies. A primary focus includes the integration of artificial intelligence within oncology, alongside investigations into the safety profiles of immunotherapies. Specifically, one study provides a systematic review of pembrolizumab-induced hemophagocytic lymphohistiocytosis in breast cancer patients, highlighting the importance of monitoring rare adverse events associated with checkpoint inhibitors. Additional research examines healthcare equity and surgical optimization. Investigations into lung cancer screening emphasize the impact of geographic accessibility on screening completion rates within urban safety-net populations. Furthermore, clinical studies evaluate surgical outcomes for melanoma, comparing the efficacy of 1-cm versus 2-cm margins for thick tumors located at difficult anatomical sites. These contributions, authored by researchers such as Irbaz Bin Riaz, Peter D. Stetson, and Amy E. Hughes, reflect a trend toward refining treatment protocols and improving access to preventative care.

Top Authors

AuthorPapers
Barbara D. Lam1

Papers

Title
Artificial Intelligence in Oncology
CRE24-035: Pembrolizumab-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Breast Cancer: A Case Report and Systematic Review of the Literature
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
Local Recurrence and Survival in Patients With Melanoma >2 mm in Thickness at Difficult Sites Treated With 1-cm Versus 2-cm Margins